Veronica Byfield Sköld

Amministratore Delegato presso BioLamina AB

Consumer Services

Health Technology

Consumer Non-Durables

Profilo

Veronica Byfield Sköld is currently the Chief Executive Officer at BioLamina AB.
Previously, she worked as the Chief Sales Officer at Clemondo Group AB.
She holds a graduate degree from the Royal Institute of Technology and an undergraduate degree from IHM Business School AB.

Posizioni attive di Veronica Byfield Sköld

Società	Posizione	Inizio
BioLamina AB BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.	Amministratore Delegato	01/10/2021

Tutte le posizioni attive di Veronica Byfield Sköld

Precedenti posizioni note di Veronica Byfield Sköld

Società	Posizione	Fine
CLEMONDO GROUP AB	Vendite & Marketing	-

Vedi nel dettaglio l'esperienza di Veronica Byfield Sköld

Formazione di Veronica Byfield Sköld

Royal Institute of Technology	Graduate Degree
IHM Business School AB	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Veronica Byfield Sköld

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
CLEMONDO GROUP AB	Consumer Non-Durables

Aziende private	1
BioLamina AB BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.	Health Technology